Trials / Completed
CompletedNCT00489918
Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis
A Dose Ranging Study of the Effects of Macroflux® PTH Compared With Macroflux® Placebo and FORTEO® in Postmenopausal Women With Osteoporosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Zosano Pharma Corporation · Industry
- Sex
- Female
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-center study to determine effects of various doses of Macroflux Parathryroid Hormone (PTH) in women with osteoporosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | teriparatide | Macroflux® patch applied to the abdomen for 30 minutes daily |
| DRUG | teriparatide | FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-04-01
- Completion
- 2008-08-01
- First posted
- 2007-06-21
- Last updated
- 2018-07-31
- Results posted
- 2018-07-31
Source: ClinicalTrials.gov record NCT00489918. Inclusion in this directory is not an endorsement.